Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program

Core Viewpoint - Centessa Pharmaceuticals plc (NASDAQ:CNTA) has achieved a new all-time high due to a planned fundraising program that could generate up to $287.5 million in fresh funds [1][3]. Fundraising Details - Centessa plans to issue over 11.6 million new American depositary shares (ADS) at a price of $21.50 each, with each ADS representing one ordinary share [2]. - The company has granted underwriters a 30-day option to purchase an additional 1,744,186 ADS at the same price [3]. - The fundraising offer is expected to close on November 14, subject to closing conditions [3]. Financial Performance - In the third quarter, Centessa reported a widened net loss of $54.89 million, a 29% increase from $42.57 million in the same period last year [4]. - The operating loss increased by 15.9% to $53.79 million from $46.4 million year-on-year, primarily due to higher operating expenses related to research and development initiatives [4].